Dutch private company specializing in 3D biological visualization and imaging, embedded in European genomics and cell biology research networks.
Surfrender is a Netherlands-based private company that contributes specialized imaging, 3D modeling, and visualization expertise to academic life sciences research consortia. In both H2020 projects, they participated as a third-party associate rather than a direct grant recipient — a profile typical of companies that host early-stage doctoral researchers or provide proprietary tools within MSCA Innovative Training Networks. Their involvement in projects on cell division (DivIDe) and chromatin architecture (ChromDesign) points to a company with capability in biological structure visualization or computational modeling of cellular and genomic systems. The company name itself — surfrender — is strongly indicative of 3D surface rendering, placing them at the intersection of scientific visualization software and fundamental life sciences research.
Both DivIDe and ChromDesign involve imaging, modeling, and design themes consistent with a company providing 3D rendering or visualization tools for biological data — reinforced by the company name itself.
ChromDesign (2018–2023) explicitly lists genomics, 3D genomics, and translational research as keywords, indicating direct engagement with the structural analysis of chromatin.
DivIDe (2016–2020) covered cell division from human oocyte to synthetic biology, suggesting surfrender contributed visualization or modeling capacity to this multidisciplinary domain.
Participation as third party in two MSCA-ITN networks signals an established practice of hosting early-stage researchers and bridging academic research with industrial workflows.
In the earlier project DivIDe (2016–2020), surfrender's involvement centered on cell division biology — spanning human oocyte to synthetic biology — but left no keyword footprint, suggesting a supporting or infrastructure role at that stage. By ChromDesign (2018–2023), the keyword profile sharpens considerably: imaging, modeling, design, genomics, 3D genomics, and translational research all appear explicitly, pointing to a more active and visible contribution to computational and structural genomics. The overall arc moves from generalist life sciences support toward a more defined specialization in 3D genome visualization and chromatin modeling.
Surfrender is moving deeper into structural and 3D genomics — a field with growing demand for specialized visualization tools in both basic research and clinical genomics translation.
Surfrender has operated exclusively as a third-party associate in H2020, meaning they contribute without holding a formal beneficiary status — a deliberate positioning that lets them engage in research networks without taking on the administrative burden of direct grant management. Their 23 consortium partners across 9 countries reflect the large, pan-European composition of MSCA-ITN networks rather than independently cultivated relationships. This suggests a partnership model in which they offer focused industrial expertise or hosting capacity to academic-led consortia rather than driving projects themselves.
Through two MSCA training networks, surfrender has touched 23 unique consortium partners across 9 European countries — a broad reach achieved indirectly via the large ITN structure rather than through bilateral network-building. Their collaborations are concentrated in research-excellence academic groups, primarily in life sciences and molecular biology.
Surfrender occupies an unusual niche as a non-academic private company — and non-SME — embedded in fundamental research training networks, which typically struggle to attract industrial partners with genuine technical depth in visualization and modeling. For a consortium builder, they offer an industrial associate profile experienced in 3D biological imaging and genomics without the overhead of a large contract research organization. That said, with limited public data available, the specifics of their commercial offering remain difficult to verify independently.
